LBT-SA7 / LimmaTech Biologics - LARVOL DELTA

LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 (Businesswire) - "LimmaTech Biologics AG...announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7....Initial results are anticipated in the second half of 2025."

Financing • P1 data • Trial status • Infectious Disease